Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies

HIGHLIGHTS

• who: Jason A. Mouabbi from the Study population and variables Approval was obtained from the institutional review board at The University of Texas MD Anderson Cancer Center (MDACC, approval noPA18-0386). A waiver of consent was obtained to ensure ethical standards of data use due to the retrospective nature of npj Breast Cancer (2022) , have published the paper: Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies, in the Journal: (JOURNAL) of December/31,/2021
• what: Similarly, the study showed that there was no difference in outcomes when patients . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.